teleo-codex/domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence-for-tonic-phasic-divergence.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	related
claim	health	After years of multi-dose GLP-1 prescribing, no systematic dose-response study on psychiatric outcomes exists, creating a critical evidence gap for a mechanism with known dose-dependent effects	experimental	Sa et al., Diabetes Obesity and Metabolism 2026 — systematic review of 80 RCTs	2026-05-06	Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses	vida	health/2026-pmc12673456-glp1-psychiatric-systematic-review.md	structural	Sa et al.	medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific

Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses

This systematic review explicitly identifies the complete absence of human dose-response data on GLP-1 psychiatric effects as a major evidence gap. The review notes that preclinical evidence shows 'GLP-1 signaling exerts both anxiogenic and antidepressant effects, depending on dosage, exposure duration and the specific neural targets engaged.' Despite this mechanistic understanding, and despite years of clinical use at multiple dose levels (semaglutide 0.5mg, 1mg, 2mg; tirzepatide 2.5mg-15mg), no systematic dose-response study has been conducted on psychiatric outcomes. The review's mechanism section explains that GLP-1's 'activation of the HPA axis and its engagement of brain regions involved in emotion regulation' suggests dose-dependent effects, yet the human evidence base contains no data to test this hypothesis. This gap is particularly striking given that the tonic/phasic receptor occupancy hypothesis predicts fundamentally different psychiatric effects at weight-loss doses versus lower doses, but clinical trial infrastructure has not been deployed to measure this. The absence is structural: most RCTs excluded individuals with moderate-to-severe mood disorders, and 'short follow-up periods restrict insight into long-term psychiatric safety.' The review categorizes anhedonia as a 'potential adverse outcome' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' — not because the effect doesn't exist, but because no validated hedonic measurement instrument (like SHAPS) has been systematically deployed in GLP-1 trials.